Today: 21 May 2026
Ondas (ONDS) stock closes higher as resale filing and Jan. 16 investor day set up next catalyst
7 January 2026
2 mins read

Ondas (ONDS) stock closes higher as resale filing and Jan. 16 investor day set up next catalyst

New York, Jan 6, 2026, 21:12 (EST) — Market closed

  • ONDS ended Tuesday at $12.84.
  • Ondas will host a virtual OAS investor day on Jan. 16 to update its 2026 plan and financial outlook.
  • A fresh SEC filing follows a prospectus supplement that covers share resales by certain stockholders.

Ondas Holdings Inc (ONDS) shares closed up about 2.5% on Tuesday at $12.84, as investors looked ahead to a Jan. 16 investor day where the company plans to outline its 2026 outlook. The stock has also drawn attention since a prospectus supplement filed on Monday registered shares for resale by certain stockholders.

The timing matters because Ondas has become a high-volatility trade in early January, and supply headlines can hit harder when a stock is moving fast. A “prospectus supplement” is an SEC document that updates a prior registration and can allow existing holders to sell shares into the market, even though it does not necessarily mean sales will happen.

A prospectus supplement dated Jan. 5 covers the resale of 2,389,203 shares by two stockholders, including Privet Ventures LLC — an investment company owned by Chief Executive Eric Brock — and Peter Higgins, the document showed. The shares were issued on Jan. 5 after holders converted notes and warrants at Ondas Autonomous Systems and exchanged the resulting stock for Ondas common shares; Ondas said it will not receive proceeds from any sales. Each holder agreed not to sell more than 5% of average daily trading volume in any single day, according to the prospectus.

Ondas said the Jan. 16 virtual investor day will focus on its Ondas Autonomous Systems unit, with updates on unmanned aerial systems and ground robots and counter-UAS, or anti-drone, products. Management said it expects to present an updated 2026 business plan, review its “Core+” growth program and discuss capital allocation, followed by a question-and-answer session. Ondas Holdings Inc.

The stock has swung sharply. Shares jumped 13.7% on Monday and rose 2.47% on Tuesday after trading between $11.96 and $12.93 in the latest session, according to price data.

Ondas also pointed to momentum in autonomous systems orders late last week, saying it had received about $10 million in new purchase orders across its portfolio.

Ondas’ autonomous systems push puts it in the same defense-and-security spending lane as drone maker AeroVironment and defense contractor Kratos, among others, where contract timing and production ramp can drive sharp moves in small-cap names.

Broader markets head into Wednesday with traders watching U.S. labor-market readings — including the ADP employment report ahead of Friday’s nonfarm payrolls — for clues on interest-rate expectations and risk appetite.

But the resale registration underscores a key uncertainty: registered holders are not required to sell, yet any steady stream of stock into the market could cool momentum. Investors also risk disappointment if Ondas’ Jan. 16 outlook does not match the stock’s recent pricing.

For the next session, traders will watch whether the shares hold above $12 and can retest $13 after this week’s spike. The next scheduled company catalyst is Ondas’ OAS investor day on Jan. 16 at 10:00 a.m. ET.

Stock Market Today

  • Sudarshan Colorants India's Earnings Show Potential Despite Profit Dip
    May 20, 2026, 8:53 PM EDT. Sudarshan Colorants India Limited (NSE:SUDARCOLOR) reported weaker profits last quarter, impacted by ₹50 million in unusual expenses that are unlikely to recur, suggesting potential profit rebound. The company's earnings per share (EPS) are growing strongly, indicating solid underlying business performance. Investors should consider balance sheet strength and monitor two identified warning signals, one considered significant. While profit was soft this time, analysts view Sudarshan Colorants' earnings outlook as cautiously optimistic, citing quality income statement elements and possible earnings improvements in the next quarter.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Vertiv stock (VRT) whipsaws after Nvidia CES cooling claim; earnings next in focus
Previous Story

Vertiv stock (VRT) whipsaws after Nvidia CES cooling claim; earnings next in focus

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Next Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Go toTop